Video

Dr. Advani on EPOCH-R in B Cell Lymphoma

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Dose-adjusted EPOCH-R is an infusion chemotherapy that uses similar drugs to R-CHOP. In preliminary data, patients overcame poor prognostic significance of Bcl-2 overexpression.

While the results of upcoming trials will give more information, Advani says, dose-adjusted EPOCH-R has become the standard of care in patients with primary mediastinal B-cell lymphoma. In this disease, treatment with R-CHOP usually requires radiotherapy as well but with EPOCH-R alone, cure rates are well above 90% and no radiotherapy is needed.

Related Videos
Minoo Battiwalla, MD, MS
Cynthia X. Ma, MD, PhD
Jyoti Patel, MD
Leo I. Gordon, MD
Bertram Yuh, MD, MISM, MSHCPM
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.